Interesting DXCM Put And Call Options For March 13th

DexCom (DXCM) is trading at $72.52 and the article highlights two options strategies: selling a $72 put (bid $2.50) which nets an effective purchase basis of $69.50 and is calculated to have a 57% chance of expiring worthless, yielding 3.47% (29.50% annualized) if so. A covered-call using the $74 strike (bid $2.90) would produce a 6.04% total return if called by the March 13 expiration with a 49% chance of expiring worthless, while implied volatilities are ~51% (put) and 53% (call) versus a 12-month realized volatility of 45%.

Analysis

Market structure: Short-dated option sellers and cash-secured put writers are the immediate winners if DXCM remains around $72; selling the Mar-13 $72 put nets $2.50 premium (3.47% yield over ~2 weeks annualized 29.5%). Market-makers and volatility sellers also benefit because implied vol (51–53%) exceeds realized TTM volatility (45%), implying option premium is rich relative to recent realized moves. Buyers of uncovered upside are losers if shares grind sideways or decline and calls expire worthless.

Risk assessment: Tail risks for DXCM are regulatory/clinical news, reimbursement shifts, or supply-chain disruptions that could move the stock >15–30% quickly — low-probability but high-impact for option sellers. Immediate horizon (days–weeks) is dominated by theta decay and gamma risk into Mar 13 expiry; medium term (1–3 months) by quarterly results / FDA headlines; long term driven by adoption trends in CGM devices and reimbursement policy over quarters. Hidden dependency: assignment risk and forced buy-in liquidity squeeze for puts if price gaps below strikes overnight; correlation with rates/healthcare capex can amplify moves.

Trade implications: Given IV>realized, prefer premium-selling with defined risk: cash-secured put or vertical spreads over naked short exposure. For directional exposure use covered calls to harvest 6% in two weeks or buy call spreads if expecting >8–10% move to avoid IV decay. Cross-asset: a large move in DXCM will have negligible bond/FX impact but could reprice med-tech short vol proxies and raise sector IV.

Contrarian angles: Consensus highlights yields but underplays assignment and fundamental risk — selling premium is attractive only if you accept owning DXCM at adjusted basis ~$69.50. Historical parallels: med-device IV often mean-reverts post-earnings; if DXCM posts a clean beat IV could collapse and short premium trades profit. Unintended consequence: aggressive short-put sizing can force deleveraging if a gap-down triggers assignment across funds.

Key Decisions for Investors

• Sell cash-secured DXCM Mar-13 $72 put (receive $2.50) as a tactical 1–3% portfolio allocation to establish a long position at an effective basis of $69.50; size so max cash commitment equals notional of position and set a hard stop if DXCM closes below $66 on daily basis (limit further assignment).
• Establish a covered-call entry: buy DXCM up to 2% portfolio and sell Mar-13 $74 calls for $2.90 to lock a 6.04% two-week gross return; if DXCM rallies >5% above $74 (i.e., >$77.70) buy back calls to avoid leaving >10% upside on the table.
• If preferring defined-risk premium-selling, sell a put spread: sell Mar-13 $72 put and buy Mar-13 $68 put (ratio 1:1) sized 1–2% portfolio to cap downside; target net credit ≥$1.00 and max loss limited to $3.00 per spread.
• Monitor: IV differential (IV_mid - RV_TTM). If IV compresses to <48% or realized vol starts trending >60% over 5–10 trading days, unwind short-vol positions within 48 hours. Prioritize news around DXCM earnings/FDA/reimbursement over next 30 days before increasing size.